- Home
- IOVA vs UWMC Comparison
IOVA vs UWMC Comparison
Compare IOVA & UWMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- UWMC
- Stock Information
- Founded
- IOVA 2007
- UWMC 1986
- Country
- IOVA United States
- UWMC United States
- Employees
- IOVA N/A
- UWMC N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- UWMC Finance: Consumer Services
- Sector
- IOVA Health Care
- UWMC Finance
- Exchange
- IOVA Nasdaq
- UWMC Nasdaq
- Market Cap
- IOVA 975.1M
- UWMC 876.2M
- IPO Year
- IOVA N/A
- UWMC N/A
- Fundamental
- Price
- IOVA $2.69
- UWMC $5.82
- Analyst Decision
- IOVA Buy
- UWMC Hold
- Analyst Count
- IOVA 11
- UWMC 7
- Target Price
- IOVA $11.90
- UWMC $5.54
- AVG Volume (30 Days)
- IOVA 16.7M
- UWMC 10.2M
- Earning Date
- IOVA 08-07-2025
- UWMC 08-07-2025
- Dividend Yield
- IOVA N/A
- UWMC 6.87%
- EPS Growth
- IOVA N/A
- UWMC 112.84
- EPS
- IOVA N/A
- UWMC 0.07
- Revenue
- IOVA $241,525,000.00
- UWMC $2,622,828,000.00
- Revenue This Year
- IOVA $86.62
- UWMC $16.65
- Revenue Next Year
- IOVA $69.13
- UWMC $16.18
- P/E Ratio
- IOVA N/A
- UWMC $87.80
- Revenue Growth
- IOVA 636.99
- UWMC 13.45
- 52 Week Low
- IOVA $1.64
- UWMC $3.80
- 52 Week High
- IOVA $12.51
- UWMC $9.74
- Technical
- Relative Strength Index (RSI)
- IOVA 54.92
- UWMC 72.08
- Support Level
- IOVA $2.44
- UWMC $5.27
- Resistance Level
- IOVA $2.85
- UWMC $5.68
- Average True Range (ATR)
- IOVA 0.24
- UWMC 0.30
- MACD
- IOVA -0.00
- UWMC 0.09
- Stochastic Oscillator
- IOVA 83.16
- UWMC 95.56
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.